Neumora Therapeutics (NMRA) Debt to Equity (2025 - 2026)
Neumora Therapeutics' quarterly Debt to Equity came in at $0.75 in Q1 2026, up 42.73% quarter-over-quarter from $0.52 in Q4 2025.
Neumora Therapeutics has reported Debt to Equity for 2 years, with the latest figure at $0.75 in Q1 2026.
- For the quarter ending Q1 2026, Debt to Equity changed N/A year-over-year to $0.75; the trailing twelve-month figure through Mar 2026 stood at $0.75 (changed N/A YoY), and the FY2025 full-year result was $0.52, changed N/A from the prior year.
- Debt to Equity for Q1 2026 stood at $0.75, up from $0.52 in the prior quarter.
- The five-year high for Debt to Equity was $0.75 in Q1 2026, with the low at $0.11 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.06 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | 0.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.75 |
| Dec 31, 2025 | 0.52 |
| Sep 30, 2025 | 0.15 |
| Jun 30, 2025 | 0.11 |